Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
出版年份 2023 全文链接
标题
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma
作者
关键词
-
出版物
CANCER CELL
Volume 41, Issue 4, Pages 791-806.e4
出版商
Elsevier BV
发表日期
2023-04-10
DOI
10.1016/j.ccell.2023.03.010
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
- (2022) Claire F Friedman et al. Journal for ImmunoTherapy of Cancer
- Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy
- (2022) Yangfu Jiang et al. Journal of Hematology & Oncology
- Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
- (2022) Julia R. Dixon-Douglas et al. Current Oncology Reports
- Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
- (2022) Meng Wang et al. Genome Medicine
- Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
- (2021) April A N Rose et al. Journal for ImmunoTherapy of Cancer
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- (2021) Kevin Litchfield et al. CELL
- Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
- (2021) Dan P Zandberg et al. Journal for ImmunoTherapy of Cancer
- FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
- (2021) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
- (2021) Dorte Schou Nørøxe et al. Molecular Oncology
- Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment
- (2021) Alba Nicolas-Boluda et al. eLife
- DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134.
- (2021) Michael B. Atkins et al. JOURNAL OF CLINICAL ONCOLOGY
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
- (2020) Mary A. Wood et al. Genome Medicine
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Collagen density regulates the activity of tumor-infiltrating T cells
- (2019) Dorota E. Kuczek et al. Journal for ImmunoTherapy of Cancer
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
- (2019) Daehwan Kim et al. NATURE BIOTECHNOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
- (2019) Diane Damotte et al. Journal of Translational Medicine
- The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
- (2019) Yongfeng Wu et al. Frontiers in Oncology
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
- (2018) Noam Auslander et al. NATURE MEDICINE
- Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples
- (2018) Erica K. Barnell et al. GENETICS IN MEDICINE
- A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data
- (2018) Benjamin J. Ainscough et al. NATURE GENETICS
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits
- (2016) Hai Fang et al. Genome Medicine
- StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
- (2015) Mihaela Pertea et al. NATURE BIOTECHNOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
- (2014) F. Favero et al. ANNALS OF ONCOLOGY
- HTSeq--a Python framework to work with high-throughput sequencing data
- (2014) S. Anders et al. BIOINFORMATICS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
- (2012) Christopher T. Saunders et al. BIOINFORMATICS
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
- (2012) D. C. Koboldt et al. GENOME RESEARCH
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- (2012) Guangchuang Yu et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- SomaticSniper: identification of somatic point mutations in whole genome sequencing data
- (2011) David E. Larson et al. BIOINFORMATICS
- Molecular signatures database (MSigDB) 3.0
- (2011) A. Liberzon et al. BIOINFORMATICS
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- edgeR: a Bioconductor package for differential expression analysis of digital gene expression data
- (2009) M. D. Robinson et al. BIOINFORMATICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started